Cargando…

Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen

BACKGROUND: The objective of this study was to conduct an indirect treatment comparison between cabazitaxel, abiraterone and enzalutamide to determine the clinical efficacy and safety of cabazitaxel relative to comparators in the treatment of patients with metastatic castrate-resistant prostate canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fryzek, Jon P., Reichert, Heidi, Summers, Nicholas, Townes, Lindsay, Deuson, Robert, Alexander, Dominik D., Vanderpuye-Orgle, Jackie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895064/
https://www.ncbi.nlm.nih.gov/pubmed/29641566
http://dx.doi.org/10.1371/journal.pone.0195790
_version_ 1783313595508981760
author Fryzek, Jon P.
Reichert, Heidi
Summers, Nicholas
Townes, Lindsay
Deuson, Robert
Alexander, Dominik D.
Vanderpuye-Orgle, Jackie
author_facet Fryzek, Jon P.
Reichert, Heidi
Summers, Nicholas
Townes, Lindsay
Deuson, Robert
Alexander, Dominik D.
Vanderpuye-Orgle, Jackie
author_sort Fryzek, Jon P.
collection PubMed
description BACKGROUND: The objective of this study was to conduct an indirect treatment comparison between cabazitaxel, abiraterone and enzalutamide to determine the clinical efficacy and safety of cabazitaxel relative to comparators in the treatment of patients with metastatic castrate-resistant prostate cancer who progress on docetaxel-based therapies. METHODS: A systematic literature review was conducted to inform the network meta-analysis of cabazitaxel, abiraterone and enzalutamide. Due to a lack of head-to-head trials, studies with a comparator arm of best supportive care were included in the analysis. Overall survival, progression-free survival, and adverse events were compared within both Bayesian and Frequentist frameworks. The ratios for survival outcomes were estimated using hazard ratios (HR), and the ratios for adverse events between groups were estimated using odds ratios (ORs); uncertainty was reported as 95% confidence (Frequentist) and credible (Baysesian) Intervals. RESULTS: Three of thirteen trials identified for abstraction were relevant for analyses. Median overall survival was not statistically significantly different for abiraterone (HR = 1.04; 95% CI = 0.83–1.28) or enzalutamide (HR = 0.88; 95% CI = 0.69–1.11) when compared to cabazitaxel in the Bayesian analysis. Anaemia (OR = 3.71; 95% CI = 1.01–10.44), diarrhoea (OR = 16.60; 95% CI = 1.41–75.31) and haematuria (OR = 3.88; 95% CI = 1.03–10.09) were more likely to occur in the cabazitaxel group than the abiraterone group, while pyrexia risk was higher in cabazitaxel compared to enzalutamide (OR = 36.23; 95% CI = 1.14–206.40). Frequentist analyses produced similar results. CONCLUSIONS: The scarcity of clinical studies and lack of a common comparator limited analyses. The adverse event results must be interpreted with caution as many were based on small numbers. The results from this analysis indicate comparable survival outcomes and adverse event profiles. As these pivotal studies may not reflect the contemporary treatment landscape and patient profiles, additional research, including head-to-head clinical trials and real world observational studies, should be conducted to further elucidate the beneficial effects of these therapies.
format Online
Article
Text
id pubmed-5895064
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58950642018-05-04 Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen Fryzek, Jon P. Reichert, Heidi Summers, Nicholas Townes, Lindsay Deuson, Robert Alexander, Dominik D. Vanderpuye-Orgle, Jackie PLoS One Research Article BACKGROUND: The objective of this study was to conduct an indirect treatment comparison between cabazitaxel, abiraterone and enzalutamide to determine the clinical efficacy and safety of cabazitaxel relative to comparators in the treatment of patients with metastatic castrate-resistant prostate cancer who progress on docetaxel-based therapies. METHODS: A systematic literature review was conducted to inform the network meta-analysis of cabazitaxel, abiraterone and enzalutamide. Due to a lack of head-to-head trials, studies with a comparator arm of best supportive care were included in the analysis. Overall survival, progression-free survival, and adverse events were compared within both Bayesian and Frequentist frameworks. The ratios for survival outcomes were estimated using hazard ratios (HR), and the ratios for adverse events between groups were estimated using odds ratios (ORs); uncertainty was reported as 95% confidence (Frequentist) and credible (Baysesian) Intervals. RESULTS: Three of thirteen trials identified for abstraction were relevant for analyses. Median overall survival was not statistically significantly different for abiraterone (HR = 1.04; 95% CI = 0.83–1.28) or enzalutamide (HR = 0.88; 95% CI = 0.69–1.11) when compared to cabazitaxel in the Bayesian analysis. Anaemia (OR = 3.71; 95% CI = 1.01–10.44), diarrhoea (OR = 16.60; 95% CI = 1.41–75.31) and haematuria (OR = 3.88; 95% CI = 1.03–10.09) were more likely to occur in the cabazitaxel group than the abiraterone group, while pyrexia risk was higher in cabazitaxel compared to enzalutamide (OR = 36.23; 95% CI = 1.14–206.40). Frequentist analyses produced similar results. CONCLUSIONS: The scarcity of clinical studies and lack of a common comparator limited analyses. The adverse event results must be interpreted with caution as many were based on small numbers. The results from this analysis indicate comparable survival outcomes and adverse event profiles. As these pivotal studies may not reflect the contemporary treatment landscape and patient profiles, additional research, including head-to-head clinical trials and real world observational studies, should be conducted to further elucidate the beneficial effects of these therapies. Public Library of Science 2018-04-11 /pmc/articles/PMC5895064/ /pubmed/29641566 http://dx.doi.org/10.1371/journal.pone.0195790 Text en © 2018 Fryzek et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fryzek, Jon P.
Reichert, Heidi
Summers, Nicholas
Townes, Lindsay
Deuson, Robert
Alexander, Dominik D.
Vanderpuye-Orgle, Jackie
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title_full Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title_fullStr Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title_full_unstemmed Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title_short Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
title_sort indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895064/
https://www.ncbi.nlm.nih.gov/pubmed/29641566
http://dx.doi.org/10.1371/journal.pone.0195790
work_keys_str_mv AT fryzekjonp indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT reichertheidi indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT summersnicholas indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT towneslindsay indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT deusonrobert indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT alexanderdominikd indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen
AT vanderpuyeorglejackie indirecttreatmentcomparisonofcabazitaxelforpatientswithmetastaticcastrateresistantprostatecancerwhohavebeenpreviouslytreatedwithadocetaxelcontainingregimen